These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28078634)

  • 1. Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis.
    Saida T; Kira JI; Kishida S; Yamamura T; Ohtsuka N; Dong Q; Tibung JT
    Neurol Ther; 2017 Jun; 6(1):153-159. PubMed ID: 28078634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer L; Galetta S; Campagnolo DI; Avila R; Lee L; Rutledge D; Fox RJ
    Adv Ther; 2021 Jul; 38(7):3724-3742. PubMed ID: 34014549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
    Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
    Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.
    Saida T; Kira JI; Kishida S; Yamamura T; Ohtsuka N; Ling Y; Torii S; Lucas N; Kuesters G; Steiner D; Tibung JT;
    Neurol Ther; 2017 Jun; 6(1):39-55. PubMed ID: 27921221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.
    Dalton CM; Miszkiel KA; Barker GJ; MacManus DG; Pepple TI; Panzara M; Yang M; Hulme A; O'Connor P; Miller DH
    J Neurol; 2004 Apr; 251(4):407-13. PubMed ID: 15083284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
    Bigaut K; Fabacher T; Kremer L; Ongagna JC; Kwiatkowski A; Sellal F; Ferriby D; Courtois S; Vermersch P; Collongues N; Zéphir H; De Seze J; Outteryck O
    Mult Scler; 2021 Apr; 27(5):729-741. PubMed ID: 32643521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.
    O'Connor P; Miller D; Riester K; Yang M; Panzara M; Dalton C; Miszkiel K; Khan O; Rice G; Sheremata W;
    Mult Scler; 2005 Oct; 11(5):568-72. PubMed ID: 16193895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
    Miller DH; Soon D; Fernando KT; MacManus DG; Barker GJ; Yousry TA; Fisher E; O'Connor PW; Phillips JT; Polman CH; Kappos L; Hutchinson M; Havrdova E; Lublin FD; Giovannoni G; Wajgt A; Rudick R; Lynn F; Panzara MA; Sandrock AW;
    Neurology; 2007 Apr; 68(17):1390-401. PubMed ID: 17452584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study.
    Horakova D; Uher T; Krasensky J; Seidl Z; Ribbens A; Van Hecke W; Billiet T; Koendgen H; Freudensprung U; Hyde R; Vaneckova M
    Mult Scler Relat Disord; 2020 Nov; 46():102543. PubMed ID: 33296966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.
    Soon D; Altmann DR; Fernando KT; Giovannoni G; Barkhof F; Polman CH; O'Connor P; Gray B; Panzara M; Miller DH
    J Neurol; 2007 Mar; 254(3):306-14. PubMed ID: 17277910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Barbin L; Rousseau C; Jousset N; Casey R; Debouverie M; Vukusic S; De Sèze J; Brassat D; Wiertlewski S; Brochet B; Pelletier J; Vermersch P; Edan G; Lebrun-Frenay C; Clavelou P; Thouvenot E; Camdessanché JP; Tourbah A; Stankoff B; Al Khedr A; Cabre P; Papeix C; Berger E; Heinzlef O; Debroucker T; Moreau T; Gout O; Bourre B; Créange A; Labauge P; Magy L; Defer G; Foucher Y; Laplaud DA;
    Neurology; 2016 Feb; 86(8):771-8. PubMed ID: 26826205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Neurol Sci; 2011 Jan; 31 Suppl 3():317-20. PubMed ID: 20535514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.